Are We Right to Consider Mesenchymal Stem Cells to Be a New Perspective for Patients with Juvenile Idiopathic Arthritis?
Krzysztof OrczykElżbieta SmolewskaPublished in: Archivum immunologiae et therapiae experimentalis (2017)
Juvenile idiopathic arthritis (JIA) is the most common cause of chronic arthritis in childhood. Up to 50% of patients are resistant to standard therapy, which includes non-steroid anti-inflammatory drugs, corticosteroids, disease-modifying anti-rheumatic drugs and biologic therapies. Intra-articular injection of mesenchymal stem cells (MSCs) is proposed as a new approach to JIA treatment. MSCs can modulate inflammation via mechanisms of both adaptive and innate immune response. They are able to inhibit T and B cell proliferation, promote regulatory T cells, suppress the maturation of dendritic cells, stimulate macrophage differentiation into M2 phenotype and reduce effectiveness of natural killer cells. They also secrete plethora of soluble factors which influence joint inflammation. Recent clinical studies reviewed in the article provide promising results which may suggest including intra-articular injection of MSCs in therapy of patients with oligoarticular JIA.
Keyphrases
- juvenile idiopathic arthritis
- mesenchymal stem cells
- dendritic cells
- immune response
- regulatory t cells
- umbilical cord
- rheumatoid arthritis
- disease activity
- natural killer cells
- cell proliferation
- bone marrow
- oxidative stress
- end stage renal disease
- cell therapy
- anti inflammatory drugs
- systematic review
- ejection fraction
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- systemic lupus erythematosus
- ultrasound guided
- adipose tissue
- prognostic factors
- peritoneal dialysis
- drug induced
- early life
- cell cycle
- smoking cessation
- patient reported